Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malaria

  Free Subscription


24.05.2021

1 Acta Trop
2 J Infect Dis
5 Malar J
1 PLoS Negl Trop Dis
2 PLoS One
1 PLoS Pathog
1 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Trop

  1. SLATER L, Betson M, Ashraf S, Sargison N, et al
    Current methods for the detection of antimalarial drug resistance in Plasmodium parasites infecting humans.
    Acta Trop. 2021;216:105828.
    PubMed         Abstract available


    J Infect Dis

  2. MAHON BE, Simon J, Widdowson MA, Samai M, et al
    Baseline Asymptomatic Malaria Infection and Immunogenicity of rVSVDeltaG-ZEBOV-GP Vaccine: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).
    J Infect Dis. 2021 May 20. pii: 6278485. doi: 10.1093.
    PubMed         Abstract available

  3. DRUETZ T, Stresman G, Ashton RA, Joseph V, et al
    The Immediate Effects of a Combined Mass Drug Administration and Indoor Residual Spraying Campaign to Accelerate Progress towards Malaria Elimination in Grande-Anse, Haiti.
    J Infect Dis. 2021 May 16. pii: 6276424. doi: 10.1093.
    PubMed         Abstract available


    Malar J

  4. TADESSE Y, Irish SR, Chibsa S, Dugassa S, et al
    Malaria prevention and treatment in migrant agricultural workers in Dangur district, Benishangul-Gumuz, Ethiopia: social and behavioural aspects.
    Malar J. 2021;20:224.
    PubMed         Abstract available

  5. ADOKE Y, Zoleko-Manego R, Ouoba S, Tiono AB, et al
    A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria.
    Malar J. 2021;20:222.
    PubMed         Abstract available

  6. FAYE SLB, Lugand MM
    Participatory research for the development of information, education and communication tools to promote intermittent preventive treatment of malaria in pregnancy in the Democratic Republic of the Congo, Nigeria and Mozambique.
    Malar J. 2021;20:223.
    PubMed         Abstract available

  7. KAMAU A, Mtanje G, Mataza C, Bejon P, et al
    Spatial-temporal clustering of malaria using routinely collected health facility data on the Kenyan Coast.
    Malar J. 2021;20:227.
    PubMed         Abstract available

  8. TASSEMBEDO M, Coulibaly S, Ouedraogo B
    Factors associated with the use of insecticide-treated nets: analysis of the 2018 Burkina Faso Malaria Indicator Survey.
    Malar J. 2021;20:220.
    PubMed         Abstract available


    PLoS Negl Trop Dis

  9. BRITO-SOUSA JD, Murta F, Vitor-Silva S, Sampaio VS, et al
    Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study).
    PLoS Negl Trop Dis. 2021;15:e0009415.
    PubMed         Abstract available


    PLoS One

  10. NYASA RB, Fotabe EL, Ndip RN
    Trends in malaria prevalence and risk factors associated with the disease in Nkongho-mbeng; a typical rural setting in the equatorial rainforest of the South West Region of Cameroon.
    PLoS One. 2021;16:e0251380.
    PubMed         Abstract available

  11. YOVOGAN B, Sovi A, Padonou GG, Adoha CJ, et al
    Pre-intervention characteristics of the mosquito species in Benin in preparation for a randomized controlled trial assessing the efficacy of dual active-ingredient long-lasting insecticidal nets for controlling insecticide-resistant malaria vectors.
    PLoS One. 2021;16:e0251742.
    PubMed         Abstract available


    PLoS Pathog

  12. RAHI M, Chaturvedi R, Das P, Sharma A, et al
    India can consider integration of three eliminable disease control programmes on malaria, lymphatic filariasis, and visceral leishmaniasis.
    PLoS Pathog. 2021;17:e1009492.
    PubMed        


    Vaccine

  13. FRIEDMAN-KLABANOFF DJ, Berry AA, Travassos MA, Cox C, et al
    Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.
    Vaccine. 2021 Jan 22. pii: S0264-410X(20)31590.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malaria is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: